<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326533</url>
  </required_header>
  <id_info>
    <org_study_id>DK082878</org_study_id>
    <secondary_id>5R21DK082878-02</secondary_id>
    <nct_id>NCT01326533</nct_id>
  </id_info>
  <brief_title>Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes</brief_title>
  <official_title>Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the short-term effects of the antimalarial
      medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled
      intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin
      secretion and glucose tolerance in subjects at risk for developing Type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is approaching epidemic proportions in the United States. This study evaluates the
      mechanisms of action of a generic drug that may have effects on glucose metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>13 weeks after baseline measurement</time_frame>
    <description>Change from baseline in the insulin sensitivity index (Si)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta Cell Function</measure>
    <time_frame>13 weeks after baseline measurement</time_frame>
    <description>Change from baseline in the disposition index (DI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirteen weeks of daily hydroxychloroquine following FSIGTT testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Thirteen weeks of daily placebo following FSIGTT testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxychloroquine</intervention_name>
    <description>Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules</description>
    <arm_group_label>hydroxychloroquine</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Thirteen weeks of oral placebo provided as capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>microcellulose placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; or = 18, able to provide informed consent

          2. Body-mass index greater than or equal to 25

          3. Presence of at least one indicator of insulin resistance from the following list:

               -  Family history of Type 2 diabetes (parent, sibling)

               -  Fasting glucose 100 - 125 mg/dl

               -  Fasting serum insulin greater than or equal to 7uU/ml

               -  Personal history of gestational diabetes

          4. Negative pregnancy test for women with childbearing potential

        Exclusion Criteria:

          1. Diagnosis of diabetes mellitus Type 1 or Type 2

          2. Active autoimmune disease, chronic infection, current malignancy (excluding basal cell
             carcinoma), or other active inflammatory state that, in the opinion of the
             investigators, would affect insulin sensitivity

          3. Oral corticosteroid use in prior six months, or expectation of needing corticosteroid
             therapy in upcoming six months

          4. Known allergy or intolerance to HCQ

          5. Known glucose-6 phosphate dehydrogenase deficiency

          6. Known eye disease associated with retinal pigmentation abnormalities

          7. Known diabetic retinopathy requiring past or planned laser therapy

          8. Inability to comply with visit schedule and protocol requirements

          9. Inability to manage and take medication as instructed

         10. Current or planned pregnancy in upcoming 12 months

         11. Inability or unwillingness to use reliable method of contraception (for women of
             childbearing years, men, or men's partners with childbearing potential), such as oral
             contraceptive pills, barrier method (diaphragm and condom with spermicide),
             intrauterine device, or depo-provera injections for 3 months prior to enrollment

         12. Anemia (HGB &lt; 9)

         13. Any history of bariatric (weight loss) surgery

         14. Current use of the medication Glucophage (metformin)

         15. Weight changes of 6 pounds or more in the past 4 weeks

         16. Any other underlying or concomitant condition, which in the opinion of the principal
             investigator, could confound the results of the study or put the subject at undue risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederico Toledo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh, Montefiore Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2016</results_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Frederico Toledo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pre-diabetes</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>frequently sampled intravenous glucose tolerance testing</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydroxychloroquine</title>
          <description>13 weeks of hydroxychloroquine sulfate PO 400 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>13 weeks of placebo PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydroxychloroquine</title>
          <description>Hydroxychloroquine sulfate PO 400 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="14.5"/>
                    <measurement group_id="B2" value="44.9" spread="16.8"/>
                    <measurement group_id="B3" value="47.6" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin sensitivity (Si)</title>
          <units>10^-4 / pmol*l / min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.52" spread="0.27"/>
                    <measurement group_id="B2" value="0.58" spread="0.42"/>
                    <measurement group_id="B3" value="0.55" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta cell function (disposition index)</title>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1721" spread="2014"/>
                    <measurement group_id="B2" value="1214" spread="691"/>
                    <measurement group_id="B3" value="1483" spread="1540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <description>Change from baseline in the insulin sensitivity index (Si)</description>
        <time_frame>13 weeks after baseline measurement</time_frame>
        <population>all randomized with last observation carried forward for missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxychloroquine</title>
            <description>400 mg PO daily for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PO daily for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Change from baseline in the insulin sensitivity index (Si)</description>
          <population>all randomized with last observation carried forward for missing data</population>
          <units>10^-4/pmol*l/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.03"/>
                    <measurement group_id="O2" value="-0.11" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline value as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta Cell Function</title>
        <description>Change from baseline in the disposition index (DI)</description>
        <time_frame>13 weeks after baseline measurement</time_frame>
        <population>all randomized with last observation carried forward for missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxychloroquine</title>
            <description>400 mg PO daily for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PO daily for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Beta Cell Function</title>
          <description>Change from baseline in the disposition index (DI)</description>
          <population>all randomized with last observation carried forward for missing data</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352" spread="143"/>
                    <measurement group_id="O2" value="-218" spread="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline value as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 13 weeks of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hydroxychloroquine</title>
          <description>Hydroxychloroquine sulfate PO 400mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia or GI discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unusual or vivid dreams</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frederico Toledo</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-692-2848</phone>
      <email>.toledofs@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

